1,205 Shares in Axon Enterprise, Inc $AXON Bought by Foguth Wealth Management LLC.

Foguth Wealth Management LLC. bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,205 shares of the biotechnology company’s stock, valued at approximately $541,000.

Other institutional investors have also bought and sold shares of the company. Evergreen Capital Management LLC grew its holdings in Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares during the period. Synergy Financial Group LTD raised its position in shares of Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 19 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after purchasing an additional 19 shares during the period. Certuity LLC lifted its stake in shares of Axon Enterprise by 5.1% in the 4th quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 23 shares during the period. Finally, Pure Financial Advisors LLC boosted its position in shares of Axon Enterprise by 6.7% during the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 23 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of several recent analyst reports. Barclays decreased their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Citizens Jmp reaffirmed a “market outperform” rating and set a $700.00 price objective on shares of Axon Enterprise in a research report on Thursday, June 25th. Finally, The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research note on Thursday, May 7th. Fifteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $725.25.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $527.76 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $497.09 and a two-hundred day simple moving average of $476.61. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91. The firm has a market capitalization of $42.54 billion, a PE ratio of 211.95, a price-to-earnings-growth ratio of 10.77 and a beta of 1.38.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period last year, the firm earned $1.47 earnings per share. Analysts forecast that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $643.79, for a total transaction of $6,437,900.00. Following the completion of the transaction, the chief executive officer owned 3,040,997 shares in the company, valued at approximately $1,957,763,458.63. The trade was a 0.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the sale, the president directly owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This represents a 7.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 58,989 shares of company stock worth $30,527,983 over the last ninety days. Insiders own 4.20% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.